Download PDF
Anästhesiol Intensivmed Notfallmed Schmerzther 2004; 39(8): 456-462
DOI: 10.1055/s-2004-825736
Aktuelle Medizin und Forschung
© Georg Thieme Verlag KG Stuttgart · New York

Xenon - Edelgas mit organprotektiven Eigenschaften

Xenon - Noble Gas With Organprotective PropertiesB.  Preckel1 , N.  Weber1 , W.  Schlack1
  • 1 Klinik für Anästhesiologie (Direktor: Prof. Dr. med. Jörg Tarnow), Universitätsklinikum Düsseldorf
Further Information

Publication History

Publication Date:
20 August 2004 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Neben anästhetischen Eigenschaften bewirkt Xenon biologische Veränderungen, welche eine Organprotektion hervorrufen können. So reduziert Xenon als potenter NMDA-Rezeptor-Antagonist den über NMDA-Rezeptoren vermittelten neuronalen Schaden. Im Gegensatz zu anderen NMDA-Rezeptor-Antagonisten hat Xenon gleichzeitig selbst keine neurotoxischen Begleiteffekte. Xenon schützt zudem das Herz in Ischämie-Reperfusionssituationen. Der myokardiale Reperfusionsschaden wird durch Xenon vermindert und eine Myokardprotektion im Sinne einer pharmakologischen Präkonditionierung induziert. Die organprotektiven Eigenschaften könnten für die Verwendung von Xenon in ausgewählten klinischen Situationen sprechen.

Abstract

Besides it’s anaesthetic properties, xenon may induce biological effects that may protect various organs from ischaemia-reperfusion injury. Xenon is an antagonist of the NMDA-receptor and reduces the neuronal injury mediated via these receptors. In contrast to other NMDA-receptor antagonists, xenon has no neurotoxic side effects. Xenon also protects the heart in ischaemia-reperfusion situations. Xenon reduces the post-ischaemic reperfusion injury and offers cardioprotection by inducing pharmacological preconditioning. These organprotective properties of xenon might be useful in special clinical situations.

Schlüsselwörter

Xenon - Neuroprotektion - Myokardprotektion - Reperfusionsschaden - Präkonditionierung

Key words

Xenon - neuroprotection - myocardial protection - reperfusion injury - preconditioning

Literatur

  • 1 Cullen S C, Gross E G. The anesthetic properties of xenon in animals and human beings, with additional observations on krypton.  Science. 1951;  113 580-583
    CrossrefPubMedGoogle Scholar
  • 2 Rossaint R, Reyle-Hahn M, Schulte am Esch J, Scholz J, Scherpereel P, Vallet B, Giunta F, Del Turco M, Erdmann W, Tenbrinck R, Hammerle A F, Nagele P. Multicenter randomized comparison of the efficacy and safety of xenon and isoflurane in patients undergoing elective surgery.  Anesthesiology. 2003;  98 6-13
    CrossrefPubMedGoogle Scholar
  • 3 Dingley J, Findlay G P, Foëx P, Mecklenburgh J, Esmail M, Little R A. A closed xenon anesthesia delivery system.  Anesthesiology. 2001;  94 173-176
    PubMedGoogle Scholar
  • 4 Goto T, Suwa K, Uezono S, Ichinose F, Uchiyama M, Morita S. The blood-gas partition coefficient of xenon may be lower than generally accepted.  Br J Anaesth. 1998;  80 255-256
    PubMedGoogle Scholar
  • 5 Goto T, Saito H, Shinkai M, Nakata Y, Ichinose F, Morita S. Xenon provides faster emergence from anesthesia than does nitrous oxide-sevoflurane or nitrous oxide-isoflurane.  Anesthesiology. 1997;  86 1273-1278
    CrossrefPubMedGoogle Scholar
  • 6 Nakata Y, Goto T, Morita T. Comparison of inhalation inductions with xenon and sevoflurane.  Acta Anaesthesiol Scand. 1997;  41 1157-1161
    PubMedGoogle Scholar
  • 7 Boomsma F, Rupreht J, Man In't Veld A J, de Jong F H, Dzoljic M, Lachmann B. Haemodynamic and neurohumoral effects of xenon anaesthesia.  Anaesthesia. 1990;  45 273-278
    PubMedGoogle Scholar
  • 8 Dingley J, King R, Hughes L, Terblanche C, Mahon S P, Hepp M, Youhana A, Watkins A. Exploration of xenon as a potential cardiostable sedative: a comparison with propofol after cardiac surgery.  Anaesthesia. 2001;  56 829-835
    CrossrefPubMedGoogle Scholar
  • 9 Lachmann B, Armbruster S, Schairer W, Landstra M, Trouwborst A, van Daal G-J, Kusuma A, Erdmann W. Safety and efficacy of xenon in routine use as an inhalational anaesthetic.  Lancet. 1990;  335 1413-1415
    CrossrefPubMedGoogle Scholar
  • 10 Luttropp H H, Romner B, Perhag L, Eskilsson J, Fredriksen S, Werner O. Left ventricular performance and cerebral haemodynamics during xenon anaesthesia. A transoesophageal echocardiography and transcranial Doppler sonography study.  Anaesthesia. 1993;  48 1045-1049
    PubMedGoogle Scholar
  • 11 Preckel B, Müllenheim J, Moloschavij A, Thämer V, Schlack W. Xenon administration during early reperfusion reduces infarct size after regional ischemia in the rabbit heart in vivo.  Anesth Analg. 2000;  91 1327-1332
    CrossrefPubMedGoogle Scholar
  • 12 Toma O, Weber N C, Obal D, Preckel B, Schlack W. Xenon induces myocardial protection by preconditioning. Involvement of protein kinase C (PKC).  Anesthesiology. 2003;  Meeting Abstracts 2003 A1540
    PubMedGoogle Scholar
  • 13 Ma D, Wilhelm S, Maze M, Franks N P. Neuroprotective and neurotoxic properties of the inert gas xenon.  Br J Anaesth. 2002;  89 739-746
    CrossrefPubMedGoogle Scholar
  • 14 Ma D, Yang H, Lynch J, Franks N P, Maze M, Grocott H P. Xenon attenuates cardiopulmonary bypass-induced neurologic and neurocognitive dysfunction in the rat.  Anesthesiology. 2003;  98 690-698
    CrossrefPubMedGoogle Scholar
  • 15 Wilhelm S, Ma D, Maze M, Franks N P. Effects of Xenon on in vitro and in vivo models of neuronal injury.  Anesthesiology. 2002;  96 1485-1491
    CrossrefPubMedGoogle Scholar
  • 16 Nakata Y, Goto T, Saito H, Ishiguro Y, Terui K, Kawakami H, Tsuruta Y, Niimi Y, Morita S. Plasma concentration of fentanyl with xenon to block somatic and hemodynamic responses to surgical incision.  Anesthesiology. 2000;  92 1043-1048
    PubMedGoogle Scholar
  • 17 Yagi M, Mashimo T, Kawaguchi T, Yoshiya I. Analgesic and hypnotic effects of subanaesthetic concentrations of xenon in human volunteers: comparison with nitrous oxide.  Br J Anaesth. 1995;  74 670-673
    PubMedGoogle Scholar
  • 18 Sanders R D, Franks N P, Maze M. Xenon: no stranger to anaesthesia.  Br J Anaesth. 2003;  91 709-717
    CrossrefPubMedGoogle Scholar
  • 19 Franks N P, Dickinson R, de Sousa S L, Hall A C, Lieb W R. How does xenon produce anaesthesia?.  Nature. 1998;  396 324
    CrossrefPubMedGoogle Scholar
  • 20 Yamakura T, Harris R A. Effects of gaseous anesthetics nitrous oxide and xenon on ligand-gated ion channels: Comparison with isoflurane and ethanol.  Anesthesiology. 2000;  93 1095-1101
    PubMedGoogle Scholar
  • 21 Marubio L M, Mar A rroyo-Jimenez, Cordero-Erausquin M, Lena C, Le N overe, de Kerchove d'Exaerde A, Huchet M, Damaj M I, Changeux J P. Reduced antinociception in mice lacking neuronal nicotinic receptor subunits.  Nature. 1999;  398 805-810
    CrossrefPubMedGoogle Scholar
  • 22 Suzuki T, Koyama H, Sugimoto M, Uchida I, Mashimo T. The diverse actions of volatile and gaseous anesthetics on human-cloned 5-hydoxytryptamine 3 receptors expressed in Xenopus oocytes.  Anesthesiology. 2002;  96 699-704
    CrossrefPubMedGoogle Scholar
  • 23 Lipton S A, Rosenberg P A. Excitatory amino acids as a final common pathway for neurologic disorders.  N Engl J Med. 1994;  330 613-622
    CrossrefPubMedGoogle Scholar
  • 24 Cullen S C, Eger E I2, Cullen B F, Gregory P. Observations on the anesthetic effect of the combination of xenon and halothane.  Anesthesiology. 1969;  31 305-309
    PubMedGoogle Scholar
  • 25 Nakata Y, Goto T, Ishiguro Y, Terui K, Kawakami H, Santo M, Niimi Y, Morita S. Minimum alveolar concentration (MAC) of xenon with sevoflurane in humans.  Anesthesiology. 2001;  94 611-614
    CrossrefPubMedGoogle Scholar
  • 26 Eger E I2, Brandstater B, Saidman L J, Regan M J, Severinghaus J W, Munson E S. Equipotent alveolar concentrations of methoxyflurane, halothane, diethyl ether, fluroxene, cyclopropane, xenon and nitrous oxide in the dog.  Anesthesiology. 1965;  26 771-777
    PubMedGoogle Scholar
  • 27 Koblin D D, Fang Z X, Eger E I, Laster M J, Gong D, Ionescu P, Halsey M J, Trudell J R. Minimum alveolar concentrations of noble gases, nitrogen, and sulfur hexafluoride in rats: Helium and neon as nonimmobilizers (nonanaesthetics).  Anesth Analg. 1998;  87 419-424
    PubMedGoogle Scholar
  • 28 Fukuda T, Nakayama H, Yanagi K, Mizutani T, Miyabe M, Ohshima N, Toyooka H. The effects of 30 % and 60 % xenon inhalation on pial vessel diameter and intracranial pressure in rabbits.  Anesth Analg. 2001;  92 1245-1250
    PubMedGoogle Scholar
  • 29 Yamaguchi S, Midorikawa Y, Okuda Y, Kitajima T. Propofol prevents delayed neuronal death following transient forebrain ischemia in gerbils.  Can J Anaesth. 1999;  46 593-598
    PubMedGoogle Scholar
  • 30 Allen H L, Iversen L L. Phencyclidine, dizocilpine, and cerebrocortical neurons.  Science. 1990;  247 221
    PubMedGoogle Scholar
  • 31 Jevtovic-Todorovic V, Todorovic S M, Mennerick S, Powell S, Dikranian K, Benshoff N, Zorumski C F, Olney J W. Nitrous oxide (laughing gas) is a NMDA antagonist, neuroprotectant and neurotoxin.  Nature Med. 1998;  4 460-463
    PubMedGoogle Scholar
  • 32 Obrenovitch T P. High extracellular glutamate and neuronal death in neurological disorders.  Cause, contribution or consequence? Ann N Y Acad Sci. 1999;  890 273-286
    PubMedGoogle Scholar
  • 33 Petzelt C, Blom P, Schmehl W, Müller J, Kox W J. Prevention of neurotoxicity in hypoxic cortical neurons by the noble gas xenon.  Life Sci. 2003;  72 1909-1918
    CrossrefPubMedGoogle Scholar
  • 34 Schmidt M, Marx T, Kotzerke J, Lüderwald S, Armbruster S, Topalidis P, Schirmer U, Reinelt H. Cerebral and regional organ perfusion in pigs during xenon anaesthesia.  Anaesthesia. 2001;  56 1154-1159
    CrossrefPubMedGoogle Scholar
  • 35 Fink H, Blobner M, Bogdanski R, Hänel F, Werner C, Kochs E. Effects of xenon on cerebral blood flow and autoregulation: an experimental study in pigs.  Br J Anaesth. 2000;  84 221-225
    PubMedGoogle Scholar
  • 36 Plougmann J, Astrup J, Pedersen J, Gyldensted C. Effect of stable xenon inhalation on intracranial pressure during measurement of cerebral blood flow in head injury.  J Neurosurg. 1994;  81 822-828
    PubMedGoogle Scholar
  • 37 Frietsch T, Bogdanski R, Blobner M, Werner C, Kuschinsky W, Waschke K F. Effects of xenon on cerebral blood flow and cerebral glucose utilization in rats.  Anesthesiology. 2001;  94 290-297
    PubMedGoogle Scholar
  • 38 Nakayama H, Takahashi H, Okubo N, Miyabe M, Toyooka H. Xenon and nitrous oxide do not depress cardiac function in an isolated rat heart model.  Can J Anesth. 2002;  49 375-379
    PubMedGoogle Scholar
  • 39 Stowe D F, Rehmert G C, Kwok W M, Weigt H U, Georgieff M, Bosnjak Z J. Xenon does not alter cardiac function or major cation currents in isolated guinea pig hearts or myocytes.  Anesthesiology. 2000;  92 516-522
    PubMedGoogle Scholar
  • 40 Schroth S, Schotten U, Alkanoglu O, Reyle-Hahn M, Hanrath P, Rossaint R. Xenon does not impair the responsiveness of cardiac muscle bundles to positive inotropic and chronotropic stimulation.  Anesthesiology. 2002;  96 422-427
    PubMedGoogle Scholar
  • 41 Marx T, Wagner D, Bäder S, Görtz A, Georgieff M, Fröba G. Hemodynamics and catecholamines in anesthesia with different concentrations of xenon.  ACP. 1998;  7 215-221
    PubMedGoogle Scholar
  • 42 Picker O, Schindler A W, Schwarte L A, Preckel B, Schlack W, Scheeren T WL, Thämer V. Xenon increases total body oxygen consumption during isoflurane anaesthesia in dogs.  Br J Anaesth. 2002;  88 546-554
    CrossrefPubMedGoogle Scholar
  • 43 Preckel B, Ebel D, Müllenheim J, Fräßdorf J, Thämer V, Schlack W. The direct myocardial effects of xenon in the dog heart in vivo.  Anesth Analg. 2002;  94 545-551
    PubMedGoogle Scholar
  • 44 Hettrick D A, Pagel P S, Kersten J R, Tessmer J P, Bosnjak Z J, Georgieff M, Warltier D C. Cardiovascular effects of xenon in isoflurane-anesthetized dogs with dilated cardiomyopathy.  Anesthesiology. 1998;  89 1166-1173
    CrossrefPubMedGoogle Scholar
  • 45 Preckel B, Schlack W, Heibel T, Rütten H. Xenon produces minimal haemodynamic effects in rabbits with chronically compromised left ventricular function.  Br J Anaesth. 2002;  88 264-269
    CrossrefPubMedGoogle Scholar
  • 46 Nakata Y, Goto T, Morita S. Effects of xenon on hemodynamic responses to skin incision in humans.  Anesthesiology. 1999;  90 406-410
    PubMedGoogle Scholar
  • 47 Jennings R B, Yellon D M. Reperfusion injury. Definitions and historical background. In: Yellon DM, Jennings RB, (eds) Myocardial protection: The pathophysiology of reperfusion and reperfusion injury. New York; Raven Press 1992: 1-11
    Google Scholar
  • 48 Siegmund B, Schlüter K D, Piper H M. Calcium and the oxygen paradox.  Cardiovasc Res. 1993;  27 1778-1783
    PubMedGoogle Scholar
  • 49 Preckel B, Schlack W, Comfère T, Obal D, Barthel H, Thämer V. Effects of enflurane, isoflurane, sevoflurane and desflurane on reperfusion injury after regional myocardial ischaemia in the rabbit heart in vivo.  Br J Anaesth. 1998;  81 905-912
    PubMedGoogle Scholar
  • 50 Siegmund B, Schlack W, Ladilov Y V, Balser C, Piper H M. Halothane protects cardiomyocytes against reoxygenation-induced hypercontracture.  Circulation. 1997;  96 4372-4379
    PubMedGoogle Scholar
  • 51 Garcia-Dorado D, Inserte J, Ruiz-Meana M, González M A, Solares J, Juliá M, Barrabés J A, Soler-Soler J. Gap junction uncoupler heptanol prevents cell-to-cell progression of hypercontracture and limits necrosis during myocardial reperfusion.  Circulation. 1997;  96 3579-3586
    PubMedGoogle Scholar
  • 52 Petzelt C, Taschenberger G, Schmehl W, Kox W J. Xenon-induced inhibition of Ca2+-regulated transitions in the cell cycle of human endothelial cells.  Pflügers Arch Eur J Physiol. 1999;  437 737-744
    PubMedGoogle Scholar
  • 53 Petzelt C, Osés-prieto J, Klett F F, Schmehl W, Kox W J. Effects of xenon on intracellular Ca2+ release in human endothelial cells.  Exp Biol Online. 1997;  2 3-9
    PubMedGoogle Scholar
  • 54 Murry C E, Jennings R B, Reimer K A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium.  Circulation. 1986;  74 1124-1136
    CrossrefPubMedGoogle Scholar
  • 55 Van Winkle D M, Thornton J D, Downey J M. Cardioprotection from ischemic preconditioning is lost following prolonged reperfusion in the rabbit.  Coron Artery Dis. 1991;  2 613-619
    PubMedGoogle Scholar
  • 56 Qiu Y M, Tang X L, Park S W, Sun J Z, Kalya A, Bolli R. The early and late phases of ischemic preconditioning - A comparative analysis of their effects on infarct size, myocardial stunning, and arrhythmias in conscious pigs undergoing a 40- minute coronary occlusion.  Circ Res. 1997;  80 730-742
    PubMedGoogle Scholar
  • 57 Kitakaze M, Hori M, Morioka T, Minamino T, Takashima S, Sato H, Shinozaki Y, Chujo M, Mori H, Inoue M, Kamada T. Infarct size limiting effect of ischemic preconditioning is blunted by inhibition of 5`-Nucleotidase activity and attenuation of adenosine release.  Circulation. 1994;  89 1237-1246
    PubMedGoogle Scholar
  • 58 Tsuchida A, Liu Y, Liu G S, Cohen M V, Downey J M. alpha 1-adrenergic agonists precondition rabbit ischemic myocardium independent of adenosine by direct activation of protein kinase C.  Circ Res. 1994;  75 576-585
    PubMedGoogle Scholar
  • 59 Yao Z, Gross G J. Acetylcholine mimics ischemic preconditioning via a glibenclamide-sensitive mechanism in dogs.  Am J Physiol. 1993;  264 H2221-H2225
    PubMedGoogle Scholar
  • 60 Schultz J EJ, Hsu A K, Gross G J. Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide-sensitive mechanism in the rat heart.  Circ Res. 1996;  78 1100-1104
    PubMedGoogle Scholar
  • 61 Hartman J C, Wall T M, Hullinger T G, Shebuski R J. Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140.  J Cardiovasc Pharmacol. 1993;  21 996-1003
    PubMedGoogle Scholar
  • 62 Cope D K, Impastato W K, Cohen M V, Downey J M. Volatile anesthetics protect the ischemic rabbit myocardium from infarction.  Anesthesiology. 1997;  86 699-709
    PubMedGoogle Scholar
  • 63 Toller W G, Kersten J R, Gross E R, Pagel P S, Warltier D C. Isoflurane preconditions myocardium against infarction via activation of inhibitory guanine nucleotide binding proteins.  Anesthesiology. 2000;  92 1400-1407
    PubMedGoogle Scholar
  • 64 Cason B A, Gamperl A K, Slocum R E, Hickey R F. Anesthetic-induced preconditioning - Previous administration of isoflurane decreases myocardial infarct size in rabbits.  Anesthesiology. 1997;  87 1182-1190
    PubMedGoogle Scholar
  • 65 Kersten J R, Schmeling T J, Pagel P S, Gross G J, Warltier D C. Isoflurane mimics ischemic preconditioning via activation of K ATP channel - Reduction of myocardial infarct size with an acute memory phase.  Anesthesiology. 1997;  87 361-370
    CrossrefPubMedGoogle Scholar
  • 66 Toller W G, Kersten J R, Pagel P S, Hettrick D A, Warltier D C. Sevoflurane reduces myocardial infarct size and decreases the time threshold for ischemic preconditioning in dogs.  Anesthesiology. 1999;  91 1437-1446
    PubMedGoogle Scholar
  • 67 Novalija E, Fujita S, Kampine J P, Stowe D F. Sevoflurane mimics ischemic preconditioning effects on coronary flow and nitric oxide release in isolated hearts.  Anesthesiology. 1999;  91 701-712
    PubMedGoogle Scholar
  • 68 Toller W G, Gross E R, Kersten J R, Pagel P S, Gross G J, Warltier D C. Sarcolemmal and mitochondrial adenosine triphosphate-dependent potassium channels: mechanism of desflurane induced cardioprotection.  Anesthesiology. 2000;  92 1731-1739
    PubMedGoogle Scholar
  • 69 Uecker M, Da Silva R, Grampp T, Pasch T, Schaub M C, Zaugg M. Translocation of protein kinase C isoforms to subcellular targets in ischemic and anesthetic preconditioning.  Anesthesiology. 2003;  99 138-147
    CrossrefPubMedGoogle Scholar
  • 70 Weber N C, Wolter J I, Toma O, Schlack W, Preckel B. The noble gas xenon induces pharmacological preconditioning in the rat heart in vivo via induction of PKCe and p38 MAPK.  Naunyn Schmiedebergs Arch Pharmacol. 2004;  369 (Suppl 1) A52
    PubMedGoogle Scholar
  • 71 Carr C S, Hill R J, Masamune H, Kennedy S P, Knight D R, Tracey W R, Yellon D M. Evidence for a role for both the adenosine A1 and A3 receptors in protection of isolated human atrial muscle against simulated ischaemia.  Cardiovasc Res. 1997;  36 52-59
    CrossrefPubMedGoogle Scholar
  • 72 Speechly-Dick M E, Grover G J, Yellon D M. Does ischemic preconditioning in the human involve protein kinase C and the ATP-dependent K+ channel? Studies of contractile function after simulated ischemia in an atrial in vitro model.  Circ Res. 1995;  77 1030-1035
    PubMedGoogle Scholar
  • 73 Cleveland J C,Jr, Meldrum D R, Cain B S, Banerjee A, Harken A H. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited.  Circulation. 1997;  96 29-32
    CrossrefPubMedGoogle Scholar
  • 74 Deutsch E, Berger M, Kussmaul W G, Hirshfeld J W, Herrmann H C, Laskey W K. Adaptation to ischemia during percutaneous transluminal coronary angioplasty. Clinical, hemodynamic, and metabolic features.  Circulation. 1990;  82 2044-2051
    PubMedGoogle Scholar
  • 75 Okazaki Y, Kodama K, Sato H, Kitakaze M, Hirayama A, Mishima M, Hori M, Inoue M. Attenuation of increased regional myocardial oxygen consumption during exercise as a major cause of warm-up phenomenon.  J Am Coll Cardiol. 1993;  21 1597-1604
    PubMedGoogle Scholar
  • 76 Belhomme D, Peynet J, Louzy M, Launay J M, Kitakaze M, Menasche P. Evidence for preconditioning by isoflurane in coronary artery bypass graft surgery.  Circulation. 1999;  100 340-344
    PubMedGoogle Scholar
  • 77 Julier K, Da Silva R, Garcia C, Bestmann L, Frascarolo P, Zollinger A, Chassot P G, Schmidt E R, Turina M I, von Segesser L K, Pasch T, Spahn D R, Zaugg M. Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: a double-blinded, placebo-controlled, multicenter study.  Anesthesiology. 2003;  98 1315-1327
    CrossrefPubMedGoogle Scholar
  • 78 Schirmer U, Reinelt H, Erber M, Schmidt M, Marx T. Xenon washout during in-vitro extracorporeal circulation using different oxygenators.  J Clin Monit Comput. 2002;  17 211-215
    CrossrefPubMedGoogle Scholar
  • 79 Siegmund B, Zude R, Piper H M. Recovery of anoxic-reoxygenated cardiomyocytes from severe Ca2+ overload.  Am J Physiol. 1992;  263 H1262-H1269
    PubMedGoogle Scholar
  • 80 Siegmund B, Ladilov Y, Piper H M. Importance of Na+ for the recovery of Ca2+ control in reoxygenated cardiomyocytes.  Am J Physiol. 1994;  267 H506-H513
    PubMedGoogle Scholar

Priv.-Doz. Dr. Benedikt Preckel, DEAA

Klinik für Anästhesiologie

Universitätsklinikum Düsseldorf · Postfach 10 10 07 · 40001 Düsseldorf

Email: preckel@med.uni-duesseldorf.de

      >